Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
oleh: Jinhua Ren, QiaoXian Lin, Qi Chen, Jingjing Xu, Dabin Chen, Renli Chen, Kangni Lin, Haojie Zhu, Chenjing Ye, Xiaofeng Luo, Shaozhen Chen, Hui Kong, Qiong Lin, Nan Li, Xu Lin, Zhizhe Chen, Jianda Hu, Ting Yang
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-03-01 |
Deskripsi
Summary: Adoptive transfer of hepatitis B virus (HBV) immunity may occur following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we investigated the adoptive transfer of HBV immunity in 112 patients without HBV surface antibody (HBsAb) (HBsAb-) at the time of their first allo-HSCT. After allo-HSCT, HBV-DNA（87.5%） and HBsAg（11.1%%）cleared in HBsAg+ patients. All HBsAg- patients acquired HBsAb immediately. Nevertheless, HBsAb titers subsequently declined, and 39/67 (58.2%) patients lost HBsAb during follow-up. The 5-year overall survival (OS) was better in patients who lost HBsAb. Multivariate analysis showed that the independent risk factors for OS were lack of cytomegalovirus (CMV) clearance, acute graft-versus-host disease (aGVHD), and no HBsAb loss. Overall, adoptive immune transfer offers anti-HBV protection to patients without HBsAb, as they acquire HBsAb and clear HBV-DNA and HBsAg, while HBsAb loss after allo-HSCT predicts better survival.